Skip to content
Open menu Close menu

Dr Chris Sutton

PositionSenior Lecturer in Proteomics and Mass Spectrometry
Location2.19 ICT building
DepartmentInstitute of Cancer Therapeutics
Telephone+44 (0) 1274 236480
EmailC.W.Sutton@bradford.ac.uk
LinkedInVisit my LinkedIn profile
ORCID0000-0002-1548-5093

Research Interests (key words only)

Proteomics; mass spectrometry; breast cancer; head and neck cancer; liquid biopsies.

PhD Supervision

  • Mr Sadr-ul-Shaheed
  • Mr Masood-ul-Hassan Zaka
  • Mrs Ghasaq Kashtl

Teaching and Supervisory Responsibilities

  • Biomedical Sciences, BSc – research projects, research topics II
  • Cancer Pharmacology, Cancer Drug Discovery, Drug Toxicology and Safety Pharmacology, MSc - Module Leader for Research and Analytical Methods; Tutor - critical appraisals, Supervisor – research projects

Administrative Responsibilities

ICT Health and Safety Representative

Biography

Chris Sutton obtained his B.Sc. degree and Ph.D. in Biochemistry from University of Liverpool, with combined studies in the Department of Plant Molecular Biology, University of California, Berkeley. He was then a Postdoctoral Research Scientist at the London School of Hygiene and Tropical Medicine, investigating the mechanisms of pathogenicity of Vibrio cholerae.

He joined the premier of UK biotechnology company, Celltech Limited, as a Senior Scientist in Protein Biochemistry purifying novel proteins of therapeutic interest, and was later promoted to Group Leader of Analytical Biochemistry. With the emergence of mass spectrometry for protein characterisation, he moved to ThermoFinnigan and developed novel applications for matrix assisted laser desorption mass spectrometry (MALDI MS) including pioneering work in proteomics. He joined Kratos Analytical as MALDI MS Product Manager and was responsible for the marketing and promotion, including co-ordinating the research activity of a worldwide group of 25 application specialists who were developing MALDI MS solutions for the future. He was subsequently promoted to Business Manager for the product lines with a staff of 50, doubling revenues during this time to 10 million USD per annum.

Since August 2005, Chris has joined the Institute of Cancer Therapeutics in the University of Bradford as Senior Lecturer in Proteomics Chemistry and Mass Spectrometry. With the support of Yorkshire Cancer Research, he has develop three key areas of research (1) identification of new proteins as candidate diagnostic biomarkers, (2) identification of proteins affected by the action of anticancer drugs and (3) identification of new target proteins for anticancer drug development. He has developed collaborations with academic groups in Hull, York, Sheffield and Leeds within the UK and Toronto, Cyprus, Pakistan internationally.

Study History

  • PhD (Liverpool)
  • BSc Hons (Liverpool)

Professional History

2005 - 2010: Senior Lecturer in Proteomics and Mass Spectrometry, Institute of Cancer Therapeutics, University of Bradford, Bradford, West Yorkshire
2005: Proteomics and Mass Spectrometry Consultant, Oxford Instruments, Abingdon, Oxon
2001 - 2005: Mass Spectrometry Business Manager, Shimadzu Corporation, Trafford, Manchester
1998 - 2001: Mass Spectrometry Product Manager, Shimadzu Corporation, Trafford, Manchester
1996 - 1998: Product Manager, Thermo Scientific, Hemel Hempstead, Herts.
1991 - 1996: Senior Research Biochemist, Thermo Scientific, Hemel Hempstead, Herts.
1989 - 1991: Group Leader of Analytical Biochemistry, Celltech Limited, Slough, Berks.
1985 - 1989: Senior Research Scientist, Celltech Limited, Slough, Berks.
1982 - 1985: Wellcome Foundation Postdoctoral Research Scientist, Department of Medical Microbiology, London School of Hygiene and Tropical Medicine, London

Professional Activities

  • A Director of the British Society of Proteomics Research

Research Areas

  • Proteomics and mass spectrometry

Current Projects

  • Identification of new protein targets for anticancer drug development
  • Identification of breast cancer biomarkers
  • Identification of proteins (systems biology or pharmacoproteomics) affected by the action of anticancer drugs
  • Profiling cytochrome P450s isoforms in cancer tissues and cell lines
  • Characterisation of matrix metalloproteinases from cancer-related tissues
  • Development of novel enrichment methods for improving protein recovery for proteomics applications

Research Collaborations

  • Dr Jonathan Sellars, University of Durham – CYP450 probes
  • Dr Saira Saleem, Shaukat Khanum Memorial Cancer Hospital and Research Centre – Head and neck, colorectal cancers
  • Professor Kyriacos Kyriacou, Cyprus Institute of Neurology and Genetics – breast cancer
  • Professor Matthew Collins and Dr Julie Wilson, University of York - collagen

Publications

See Dr Sutton's publications on Bradford Scholars.

  • ul-Shaheed, S., Tait, C., Kyriacou, K., Mullarkey, J., Burrill, W., Patterson, L. H., Linforth, R., Salhab, M. , Sutton, C. W. Nipple secretion - a liquid biopsy for diagnosing breast health, Proteomics Clinical Application, DOI: 10.1002/prca.201700015 (IF 3.814)

  • Sellars, J. D., Skipsey, M., ul-Shaheed, S., Gravell, S., Abumansour, H., Kashtl, G., Irfan, J., Khot, M., Pors, K., Patterson, L. H., Sutton, C. W. Rationale development of novel activity probes for the analysis of human Cytochrome P450’s ChemMedChem 11, 1122-28 (2016) doi: 10.1002/cmdc.201600134 (IF=2.968)

  • Batubara, A., Carolan, V. Loadman, P., Sutton, C., Shnyder, S. and Clench, M. R. Thin-layer chromatography/matrix-assisted laser desorption/ionisation mass spectrometry and matrix-assisted laser desorption/ionisation mass spectrometry imaging for the analysis of phospholipids in LS174T colorectal adenocarcinoma xenografts treated with the vascular disrupting agent DMXAA. Rapid Comms in Mass Spec., 129, 1288 (2015) DOI: 10.1002/rcm.7223 (IF 2.25)
  • Saleem S, Jamshed A, Faisal S, Hussain R, Tehseen M, Loya A, Sutton C., Patterns of cancer cell sphere formation in primary cultures of human oral tongue squamous cell carcinoma and neck nodes. Cancer Cell International, 14, 542 (2015) DOI 10.1186/s12935-014-0143-3

  • ul-Shaheed, S., Rustogi, N., Scally, A., Wilson, J., Thygesen, H., Loizidou, M. A., Hadjisavvas, A., Hanby, A., Speirs, V., Loadman, P., Linforth, R., Kyriacou, K., and Sutton, C. W. Identification of Stage-Specific Breast Markers using Quantitative Proteomics, J Proteome Research 12, 5696-5708 (2013) doi: 10.1021/pr400662k

  • Djidja,. M-C., Francese, S., Claude, F., Loadman, P., Sutton, C., Carolan, V. A., and Clench, M. R. Targeting of Hypoxia in AQ4N-treated Tumour Xenografts by MALDI-Ion Mobility Separation-Mass Spectrometry Imaging, Current Analytical Chemistry, 9, 212-215, (2013) CAC-EPUB-20120906-24

  • Montgomery, H., Rustogi, N., Hadjisavvas, A., Tanaka, K., Kyriacou, K. and Sutton, C. W. Proteomic profiling of breast tissue collagens and site-specific characterisation of hydroxyproline residues collagen alpha-1-(I). J Proteome Research, 11, 5890-902 (2012) DOI: 10.1021/pr300656r

  • McMahon, K. M. , Volpato, M. , Chi, H. Y., Musiwaro, P., Poterlowicz, K., Peng, Y. H., Scally, A. J., Patterson, L. H., Phillips, R. M., Sutton, C. W. New insights into metabolic pathways associated with tumor hypoxia and autophagy in 3D multicell tumor spheroids. J Proteome Research 11, 2863-2875 (2012) DOI: 10.1021/pr2012472

  • Sutton, C. W. The role of targeted chemical proteomics in pharmacology, British J. Pharmacology 2012 DOI:10.1111/j.1476-5381.2011.01778.x

In the News/Media

Share this